In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

T, O'Hare; DK, Walters; EP, Stoffregen; T, Jia; PW, Manley; J, Mestan; SW, Cowan-Jacob; FY, Lee; MC, Heinrich; MW, Deininger; BJ, Druker

doi:10.1158/0008-5472.can-05-0259

Public

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

Shared by NobleBlocks on Jun 1, 2005 • 12:00 AM UTC

Authors:

O'Hare T

Walters DK

Stoffregen EP

Abstract

Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients with chronic myelogenous leukemia (CML). Despite durable responses in most chronic phase patients, relapses have been observed and are much more prevalent in patients with advanced disease. The most common mech...

Discussions